When Should We Start Using Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Diabetic Kidney Disease?

D.D. Ivanov

Abstract


International guidelines do not recommend angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) usage in the first stage of diabetic kidney disease. It shows the view, based on a small statistical sample, that olmesartan (or possibly other ACE inhibitors/ARBs) should be used to prevent the transition of the first stage of diabetic kidney disease to the second one in type 2 diabetes mellitus.

Keywords


diabetic kidney disease; angiotensin converting enzyme inhibitors/angiotensin receptor blockers; olmesartan; international guidelines

Full Text:

PDF

References


National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes і CKD: 2012 update // Am. J. Kidney Dis. — 2012. — 60(5). — 850-886.

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease // Kidney inter., Suppl. — 2012. — 2. — 337-414. — http://www.kidney-international.org & 2012 KDIGO 340.

Diabetes Care. — 2017 Jan. — 40 (Suppl. 1). — S88-S98. — https://doi.org/10.2337/dc17-S001; http://care.diabetesjournals.org/content/40/Supplement_1/S88.

Ivanov D.D. Next Step in Chronic Kidney Disease Therapy // Kidneys. — 2016. — 2(16). — P. 10-13.




DOI: https://doi.org/10.22141/2307-1257.6.1.2017.93781

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта